Compounds > 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol
Page last updated: 2024-08-26

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol and Breast Cancer

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol has been researched along with Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chinje, EC; Harris, AL; Patterson, AV; Saunders, MP; Strafford, IJ; Talbot, DC1

Other Studies

1 other study(ies) available for 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol and Breast Cancer

ArticleYear
Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
    British journal of cancer, 1997, Volume: 76, Issue:10

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Misonidazole; NADPH-Ferrihemoprotein Reductase; Radiation-Sensitizing Agents; Tirapazamine; Transfection; Triazines; Tumor Cells, Cultured

1997